|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Darragh Fergal Lyons||CEO & Exec. Director||470k||N/D||1981|
|Mr. Pat Jennings||Chief Financial Officer||N/D||N/D||N/D|
|Jessica Bergin||Director of Investor Relations & External Reporting||N/D||N/D||N/D|
|Mr. Sean Edward Murphy||Exec. VP||N/D||N/D||1953|
|Dr. Andrew C. von Eschenbach||Chief Medical Adviser||N/D||N/D||1942|
|Ms. Fiona Dunlevy||Company Sec.||N/D||N/D||N/D|
Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Spain, rest of European Union, and internationally. It offers life-saving cell therapeutics for patients with high unmet medical need; biological therapies, which focuses on oncology, infectious, and autoimmune diseases; and treatment of recurrent vulvovaginal candidiasis, an unmet need in women's health and onychomycosis. The company also develops, manufactures, and markets injectable drugs; discovers and develops drugs for protein misfolding diseases, such as Alzheimer's and Parkinson's diseases. In addition, it focuses on the therapeutics areas of autoimmune and inflammatory disease, immuno-oncology, haematology, and infectious diseases; and platform to eliminate disease-causing bacteria in the gut microbiota. Further, the company provides company secretarial services. Malin Corporation plc was incorporated in 2014 and is based in Dublin, Ireland.
L'ISS Governance QualityScore di Malin Corporation plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.